Valeant Pharmaceuticals International

A case is being investigated against the company as well as current and former Company executive officers and directors for potential violations related to the backdating of stock options. A preliminary report revealed options granted from 1997 to present reflected incorrect measurement dates and would need to be restated. The case is focused on Valeant manipulation of stock option grant dates and exercise prices of stock options in order to boost their value. It claims Valeant may have breached their fiduciary duties.